IL10 and psoriasis: Systemic administration of recombinant IL-10 has been trialed in patients with psoriasis and Crohn’s disease and for the alleviation of post-operative inflammation (Colombel et al., 2001; Reich et al., 2001; O’Garra et al., 2008).